Transdermal penetration enhancers: Applications, limitations, and potential

Journal of Pharmaceutical Sciences

Volumn 88, Issue 10, 1999, Pages 955-958

  Finnin, Barrie C ^a   Morgan, Timothy M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; FATTY ACID; FATTY ACID ESTER; LAUROCAPRAM; PENETRATION ENHANCING AGENT; SUNSCREEN;

DRUG DELIVERY SYSTEM; DRUG PENETRATION; HUMAN; NONHUMAN; SHORT SURVEY; SKIN PENETRATION;

EID: 0032883241     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js990154g     Document Type: Short Survey

References (69)

1. Payne, R. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin. Oncol. 1998, 25, Suppl 7, 47-53.
2. Crook, D. The metabolic consequences of treating postmenopausal women with nonoral hormone replacement therapy. Br. J. Obstet. Gynaecol. 1997, 104, Suppl 16, 4-13.
3. Scheuplein, R. J.; Blank, I. H. Permeability of the skin. Physiol. Rev. 1971, 51, 702-747.
4. Mitragotri, S.; Edwards, D. A.; Blankschtein, D.; Langer, R. A mechanistic study of ultrasonically enhanced transdermal drug delivery. J. Pharm. Sci. 1995, 84, 697-706.
5. Henry, S.; McAllister, D. V.; Allen, M. G.; Prausnitz, M. R. Microfabricated microneedles: a novel approach to transdermal drug delivery. J. Pharm. Sci. 1998, 87, 922-925.
6. Guy, R. H. Iontophoresis-recent developments. J. Pharm. Pharmacol. 1998, 50, 371-374.
7. Weaver, J. C.; Vaughan, T. E.; Chizmadzhev, Y. Theory of electrical creation of aqueous pathways across skin transport barriers. Adv. Drug Delivery Rev. 1999, 35, 21-39.
8. Stoughton, R. B.; Fritsch, W. Influence of dimethyl sulfoxide on human percutaneous absorption. Arch. Dermatol. 1964, 90, 512-517.
9. Pharmaceutical Skin Penetration Enhancement; Walters, K. A.; Hadgraft, J., Eds.; Marcel Dekker: New York, 1993.
10. Barry, B. W. Vehicle effect: what is an enhancer? In Topical Drug Bioavailability, Bioequivalence, and Penetration; Shah, V. P.; Maibach, H. I., Eds.; Plenum: New York, 1993; pp 268-270.
11. Howes, D.; Guy, R.; Hadgraft, J.; Heylings, J.; Hoeck, U.; Kemper, F.; Maibach, H.; Marty, J.-P.; Merk, H.; Parra, J.; Rekkas, D.; Rondelli, I.; Schaefer, H.; Tauber, U.; Verbiese, N. Methods for asssessing percutaneous absorption. ATLA 1996, 24, 81-106.
12. In Percutaneous Absorption: Drugs-Cosmetics-Mechanisms-Methodology, 3rd ed., rev. and expanded.; Bronaugh, R. L.; Maibach, H. I., Eds.; Marcel Dekker: New York, 1999.
13. Santus, G. C.; Baker, R. W. Transdermal enhancer patent literature. J. Controlled Release 1993, 25, 1-20.
14. Osborne, D. W.; Henke, J. J. Skin penetration enhancers cited in the literature. Pharm. Technol. 1997, Nov., 58-66.
15. Mez-Mangold, L. In A History of Drugs; F. Hoffmann-La Roche: Basle, Switzerland, 1971; pp 17-27.
16. Guy, R. H. Current status and future prospects of transdermal drug delivery. Pharm. Res. 1996, 13, 1765-1769.
17. Burris, J. F.; Papademetriou, V.; Wallin, J. D.; Cook, M. E.; Weidler, D. J. Therapeutic adherence in the elderly: transdermal clonidine compared with oral verapamil for hypertension. Am. J. Med. 1991, 1A, 22S-28S.
18. Guy, R. H.; Hadgraft, J. Transdermal drug delivery: a perspective. J. Controlled Release 1987, 4, 237-251.
19. Barry, B. W. In Dermatological Formulations: Percutaneous Absorption; Marcel Dekker: New York, 1983.
20. Southwell, D.; Barry, B. W.; Woodford, R. Variations in permeability of human skin within and between specimens. Int. J. Pharm. 1984, 18, 299-309.
21. Nicolau, G.; Yacobi, A. Skin metabolism. Cutaneous first-pass effect of a transdermally absorbed prostaglandin. In Topical Drug Bioavailability, Bioequivalence, and Penetration, Shah, V. P.; Maibach, H. I., Eds.; Plenum: New York, 1993; p 292.
22. Lynch, D. H.; Roberts, L. K.; Daynes, R. A. Skin immunology. The Achilles heal to transdermal drug delivery? J. Controlled Release 1987, 6, 39-50.
23. Flynn, G. L.; Stewart, B. Percutaneous drug penetration: choosing candidates for transdermal development. Drug Dev. Res. 1988, 13, 169-185.
24. Berner, B.; Cooper, E. R. Models of skin permeability. In Transdermal Delivery of Drugs, Vol. 2; Kydonieus, A. F.; Berner, B., Eds.; CRC: Boca Raton, FL, 1987; p 44.
25. Flynn, G. L. Physicochemical determinants of skin absorption. In Principles of Route-to-Route Extrapolation for Risk Assessment, Gerrity, T. R.; Henry, C. J., Eds.; Elsevier: New York, 1990; pp 93-127.
26. Scheuplein, R. J.; Ross, L. W. Mechanism of percutaneous absorption V: percutaneous absorption of solvent deposited solids. J. Invest. Dermatol. 1974, 62, 353-360.
27. Hogan, D. J.; Maibach, H. I. Adverse dermatologic reactions to transdermal drug delivery systems. J. Am. Acad. Dermatol. 1990, 22, 811-814.
28. Coldman, M. F.; Poulsen, B. J.; Higuchi, T. Enhancement of percutaneous absorption by the use of volatile: nonvolatile systems as vehicles. J. Pharm. Sci. 1969, 58, 1098-1102.
29. Davis, A. F.; Hadgraft, J. Supersaturated solutions as topical drug delivery systems. In Pharmaceutical Skin Penetration Enhancement; Walters, K. A.; Hadgraft, J., Eds.; Marcel Dekker: New York, 1993; pp 243-267.
30. Kondo, S.; Yamanaka, C.; Sugimoto, I. Enhancement of transdermal delivery by superfluous thermodynamic potential. III. Percutaneous absorption of nifedipine in rats. J. Pharmacobio-Dyn. 1987, 10, 743-749.
31. Tsai, J.-C.; Guy, R. H.; Thornfeldt, C. R.; Gao, W.; Feingold, K. R.; Elias, P. M. Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. J. Pharm. Sci. 1996, 85, 643-648.
32. Patil, S.; Singh, P.; Szolar-Platzer, C.; Maibach, H. Epidermal enzymes as penetration enhancers in transdermal drug delivery? J. Pharm. Sci. 1996, 85, 249-252.
33. Palacio, S.; Schmitt, D.; Viac, J. Contact allergens and sodium lauryl sulphate upregulate vascular endothelial growth factor in normal keratinocytes. Br. J. Dermatol. 1997, 137, 540-544.
34. Barry, B. W. The LPP theory of skin penetration enhancement. In In Vitro Percutaneous Absorption: Principles, Fundamentals, and Applications; Bronaugh, R. L.; Maibach, H. I., Eds.; CRC: Boca Raton, FL, 1991; pp 165-185.
35. Percutaneous Penetration Enhancers; Smith, E. W.; Maibach, H. I., Eds.; CRC: Boca Raton, FL, 1995.
36. Schaefer, H.; Redelmeier, T. E. In Skin Barrier: Principles of Percutaneous Absorption, Karger: Basel, Switzerland, 1996.
37. Barry, B. W. Reflections on transdermal drug delivery. PSTT 1999, 2, 41-43.
38. Katchalsky, A.; Curran, P. F. Membrane permeability to nonelectrolytes: discontinuous systems. In Nonequilibrium Thermodynamics in Biophysics; Harvard University: Cambridge, MA, 1965; pp 113-132.
39. Stoughton, R. B., McClure, W. O. Azone: A new nontoxic enhancer of cutaneous penetration. Drug Dev. Ind. Pharm. 1983, 9, 725-744.
40. Manabe, E.; Sugibayashi, K.; Morimoto, Y. Analysis of skin penetration enhancing effect of drugs by ethanol-water mixed systems with hydrodynamic pore theory. Int. J. Pharm. 1996, 129, 211-221.
41. Berner, B.; Mazzenga, G. C.; Otte, J. H.; Steffens, R. J.; Juang, R.; Ebert, C. D. Ethanol: water mutually enhanced transdermal therapeutic system. II. Skin permeation of ethanol and nitroglycerin. J. Pharm. Sci. 1989, 78, 402-407.
42. Barry, B. W. Optimizing percutaneous absorption. In Percutaneous Absorption, Bronaugh, R. L.; Maibach, H. I., Eds.; Marcel Dekker: New York, 1985; pp 492-494.
43. Schaefer, H.; Zesch, A.; Stuttgen, G. In Skin Permeability, Springer-Verlag: Berlin, Germany, 1982; p 654.
44. Hui, X.; Hewitt, P. G.; Poblete, N.; Maibach, H. I.; Shainhouse, J. Z.; Wester, R. C. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm. Res. 1998, 15, 1589-1595.
45. Stoughton, R. B. Enhanced percutaneous absorption with 1-dodecylazacycloheptan-2-one (Azone). Arch. Dermatol. 1982, 118, 474-477.
46. Vaidyanathan, R.; Rajadhyaksha, V. J.; Kim, B. K.; Anisko, J. J. Azone. In Transdermal Delivery of Drugs, Vol. 2.; Kyodenius, A. F.; Berner, B., Eds.; CRC: Boca Raton, FL, 1987; pp 63-83.
47. Okamoto, H.; Hasida, M.; Sezaki, H. Structure-activity relationship of 1-alkyl-or 1-alkenylazacycloalkanone derivatives as percutaneous penetration enhancers. J. Pharm. Sci. 1988, 77, 418-424.
48. Lashmar, U. T.; Hadgraft, J.; Thomas, N. Topical application of penetration enhancers to the skin of nude mice: a histopathological study. J. Pharm. Pharmacol. 1989, 41, 118-122.
49. Wong, O.; Huntington, J.; Nishihata, T.; Rytting, J. H. New alkyl N,N-dialkyl-substituted amino acetates as transdermal penetration enhancers. Pharm. Res. 1989, 6, 286-295.
50. Okabe, H.; Obata, Y.; Takayama, K.; Nagai, T. Percutaneous absorption enhancing effect and skin irritation of monocyclic monoterpenes. Drug Des. Deliv. 1990, 6, 229-238.
51. Mazer, N. A.; Heiber, W. E.; Moellmer, J. F.; Meikle, A. W.; Stringham, J. D.; Sanders, S. W.; Tolman, K. G.; Odell, W. D. Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men. J. Controlled Release 1992, 19, 347-361.
52. Jordan, W. P., Jr.; Atkinson, L. E.; Lai, C. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin. Ther. 1998, 20, 80-87.
53. Wilson, D. E.; Kaidbey, K.; Boike, S. C.; Jorkasky, D. K. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin. Ther. 1998, 20, 299-306.
54. Gyurik, R. J. Chemical skin penetration enhancers - the future. In Perspectives in Percutaneous Penetration, Vol. 5a; Brain, K. R.; James, V. J.; Walters, K. A., Eds.; STS: Cardiff, Wales, UK, 1997; p 6.
55. Buyuktimkin, S.; Buyuktimkin, N.; Yeager, J. L.; Rytting, J. H. The utility of biodegradable penetration enhancers: dodecyl 2-(N,N-dimethylamino)-propionate (DDAIP) and 2-(N,N-dimethylamino)-propyl tetradecanoate (DAIPM). In Symposia Abstracts & Biographies, AAPS Annual Meeting & Exposition; Boston, MA, Nov. 1997; p 80.
56. Turunen, T. M.; Buyuktimkin, S.; Buyuktimkin, N.; Urtti, A.; Paronen, P.; Rytting, J. H. Enhanced delivery of 5-fluorouracil through shed snake skin by two new transdermal penetration enhancers. Int. J. Pharm. 1993, 92, 89-95.
57. Walters, K. A. Some novel aspects of transdermal drug delivery. In Chemical Aspects of Drug Delivery Systems; The Royal Society of Chemistry: Cambridge, UK, 1996; pp 41-51.
58. Gauthier, E. R.; Gyurik, R. J.; Krauser, S. F.; Pittz, E. P.; Samour, C. M. SEPA absorption enhancement of polar and nonpolar drugs. In Perspectives in Percutaneous Penetration, Vol. 5a; Brain, K. R.; James, V. J.; Walters, K. A., Eds.; STS: Cardiff, Wales, UK, 1997; p 79.
59. In PharmaProjects on CD-Rom, May update; PJB Publications: Richmond, Surrey, UK, 1999.
60. In Dermatotoxicology, 5th ed.; Marzulli, F. N.; Maibach, H. I. Eds.; Taylor & Francis: Washington, DC, 1996.
61. Reed, B. L.; Morgan, T. M.; Finnin, B. C.; Dermal penetration enhancers and drug delivery systems involving same. PCT Int. Appl. PCT/AU97/00091, 1997, 19 Feb.
62. Murphy, E. G.; Janousek, A.; Groves, G. A.; Fukuda, M.; Naganuma, M. Regulatory aspects. In Sunscreens. Development, Evaluation, and Regulatory Aspects, 2nd ed.; Lowe, N. J.; Shaath, N. A.; Pathak, M. A., Eds.; Marcel Dekker: New York, 1997; pp 201-260.
63. Funk, J. O.; Dromgoole, S. H.; Maibach, H. I. Sunscreen intolerance. Dermatol. Clin. 1995, 13, 473-481.
64. Bakalova, M. V.; Morgan, T. M.; Reed, B. L.; Finnin, B. C. The effect of pretreatment with new 'safe' penetration enhancers on the diffusion of NSAIDs across shed snake skin. In Perspectives in Percutaneous Penetration, Vol. 5a, Brain, K. R.; James, V. J.; Walters, K. A., Eds.; STS: Cardiff, UK, 1997; p 78.
65. Finnin, B. C.; Morgan, T. M.; Klose, K. T.; Bakalova, M. V.; Taylor, D. A.; Reed, B. L. Enhancement of epidermal penetration of NSAIDs by padimate O, octyl salicylate and octyl methoxycinnamate. AAPS Annual Meeting. Pharm. Res. 1997, 14, S304.
66. Morgan, T. M.; Reed, B. L.; Finnin, B. C. Enhanced skin permeation of sex hormones with novel topical spray vehicles. J. Pharm. Sci. 1998, 87, 1213-1218.
67. Klose, K. T.; Taylor, D. A.; Reed, B. L.; Finnin, B. C.; Enhanced percutaneous penetration of ibuprofen determined by microdialysis in conscious rats. In Perspectives in Percutaneous Penetration, Vol. 5a, Brain, K. R.; James, V. J.; Walters, K. A., Eds.; STS: Cardiff, UK, 1997; p 77.
68. Morgan, T. M.; Parr, R. A.; Reed, B. L.; Finnin, B. C. Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol. J. Pharm. Sci. 1998, 87, 1219-1225.
69. Morgan, T. M.; O'Sullivan, H. M. M.; Reed, B. L.; Finnin, B. C. Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol. J. Pharm. Sci. 1998, 87, 1226-1228.